Aclaris Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Aclaris Therapeutics

21/02/2025 13:38

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
25 (estimated) for the period ending December 31 2024
    * The Wayne Pennsylvania-based  company is expected to
report a
88.0% decrease in revenue to $2.108 million from $17.57 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Aclaris Therapeutics Inc
is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $7.50​, above​ its last closing price
of $2.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  0.04        -0.01      -0.11     Missed  -1,826
                                                        .4
 Jun. 30 2024  -0.20       -0.20      -0.15     Beat    26.6
 Mar. 31 2024  -0.26       -0.29      -0.24     Beat    16​
 Dec. 31 2023  -0.33       -0.34      -0.02     Beat    94.2
 ​​Sep.        -0.47       -0.48      -0.41     Beat    14.6
 30 2023                                                
 Jun. 30 2023  -0.44       -0.45      -0.42     Beat    6.7​
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6
 Dec. 31 2022  -0.45       -0.45      -0.41     Beat    8
 This summary was machine generated February 21 at 13:38 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)